End-To-End mRNA Services at Curia

Curia connects DNA template production, messenger RNA (mRNA) process development and GMP drug substance manufacturing with lipid nanoparticle (LNP) formulation and fill-finish. Its U.S. mRNA offering includes experience producing RNA up to 16 kilobases for clinical use, with support for both non-amplifying and self-amplifying RNA. The resource also outlines complementary lipid manufacturing capabilities.

Download White Paper

From DNA template to clinical supply

• Drug substance development and manufacturing. Capabilities include cell-free enzymatic synthesis, co-transcriptional and enzymatic capping, and modified or native nucleotides. The resource describes a 0.1–40 L production range and analytical support for batch release.
• Experience with longer RNA constructs. Curia’s offering covers conventional mRNA and self-amplifying RNA. The resource includes a client perspective from Replicate Bioscience on scaling longer RNA for a Phase 1 clinical trial.
• Formulation and fill-finish connections. LNP formulation capabilities include solvent injection and microfluidics, supported by analytics and aseptic filling. Curia’s lipid manufacturing services address custom ionizable lipids, PEG lipids and phospholipids through its international network.

Download the full overview for the drug substance and drug product workflows, indicative stage timelines, filling specifications and lipid manufacturing options. These details provide a starting point for defining a program-specific development plan.

Explore mRNA process development
Explore LNP formulation